| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6184474 | Gynecologic Oncology | 2013 | 5 Pages |
Abstract
Radiation and gemcitabine/cisplatin for patients with stage IIB to IVA cervical cancer are not cost-effective. The increased financial burden of radiation with gemcitabine/cisplatin and associated toxicities appears to outweigh the benefit of increased 3-year PFS and is primarily dependent on chemotherapy drug costs.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
B. Smith, D.E. Cohn, A. Clements, B.J. Tierney, J.M. Jr.,